Cyclic GMP-dependent protein kinase 1 (PKG1) mediates presynaptic nociceptive long-term potentiation (LTP) in the spinal cord and contributes to inflammatory pain in rodents but the present study revealed opposite effects in the context of neuropathic pain. We used a set of loss-of-function models for in vivo and in vitro studies to address this controversy: peripheral neuron specific deletion (SNS-PKG1), inducible deletion in subsets of neurons (SLICK-PKG1) and redox-dead PKG1 mutants. In contrast to inflammatory pain, SNS-PKG1 mice developed stronger neuropathic hyperalgesia associated with an impairment of nerve regeneration, suggesting specific repair functions of PKG1. Although PKG1 accumulated at the site of injury, its activity was lost in the proximal nerve due to a reduction of oxidation-dependent dimerization, which was a consequence of mitochondrial damage in injured axons. In vitro, PKG1 deficiency or its redox-insensitivity resulted in enhanced outgrowth and reduction of growth cone collapse in response to redox signals, which presented as oxidative hotspots in growing cones. At the molecular level, PKG1 deficiency caused a depletion of phosphorylated cofilin, which is essential for growth cone collapse and guidance. Hence, redox-mediated guidance required PKG1 and consequently, its deficiency in vivo resulted in defective repair and enhanced neuropathic pain after nerve injury. PKG1-dependent repair functions will outweigh its signaling functions in spinal nociceptive LTP, so that inhibition of PKG1 is no option for neuropathic pain.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5156608PMC
http://dx.doi.org/10.1016/j.redox.2016.12.004DOI Listing

Publication Analysis

Top Keywords

neuropathic pain
16
protein kinase
8
pkg1
8
inflammatory pain
8
repair functions
8
pkg1 deficiency
8
growth cone
8
cone collapse
8
pain
6
neuropathic
5

Similar Publications

Aim: St. John\'s Wort Oil (JWO) has a sedative property and it is used traditionally for the treatment of depression, neuralgia and excitability. JWO has been shown to have anticancer activity via apoptosis in glioblastoma cells.

View Article and Find Full Text PDF

Exoskeleton Training for Spinal Cord Injury Neuropathic Pain (ExSCIP): Protocol for a Phase 2 Feasibility Randomised Trial.

HRB Open Res

September 2024

UCD School of Public Health, Physiotherapy and Sports Science, Health Sciences Centre, University College Dublin, Dublin, Leinster, Ireland.

Background: Following Spinal Cord Injury (SCI), 53% of people develop neuropathic pain (NP). NP can be more debilitating than other consequences of SCI, and a persistent health issue. Pharmacotherapies are commonly recommended for NP management in SCI, although severe pain often remains refractory to these treatments in many sufferers.

View Article and Find Full Text PDF

Objective: Demonstrate the superiority of percutaneous balloon compression (PBC) in the treatment of primary trigeminal neuralgia (PTN) compared to trigeminal microvascular decompression (MVD).

Methods: Clinical data, including immediate, short-term, and long-term pain relief, complications, duration of the operation, and postoperative hospital stay, were retrospectively analyzed for 114 patients diagnosed with PTN who were treated with either PBC or MVD between January 2018 and December 2021.

Results: There were no statistically significant differences observed in the pain relief rates between the two surgical methods at 24 h postoperatively (MVD: 91.

View Article and Find Full Text PDF

Introduction: Conventional management approaches have been challenged in dealing with zoster-related trigeminal neuralgia. Percutaneous trigeminal ganglion stimulation (TGS) has been rarely reported as a potential treatment option for alleviating pain associated with this condition. The present study investigated the application of percutaneous TGS in a series of patients suffering from Zoster-related trigeminal neuralgia to evaluate its potential efficacy of pain relief.

View Article and Find Full Text PDF

Background: There is no established treatment for the acute exacerbation of trigeminal neuralgia. We aimed to investigate the efficacy and safety of intravenous fosphenytoin for this disease.

Methods: We conducted a retrospective observational study of data from 41 patients with trigeminal neuralgia who received intravenous fosphenytoin therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!